Inovio (NASDAQ: INO) wins FDA accelerated approval for DNA immunotherapy Voceryq

The US Food and Drug Administration granted accelerated approval on 30 October to Voceryq, formerly INO-3107, from Inovio Pharmaceuticals, to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis. The agency described it as the first plasmid DNA-based immunotherapy for the disease. In the pivotal study, 7 of 26 patients in the efficacy population, or 27%, needed no surgery in the 12 months after treatment.

The evidence is modest in scale. The open-label RRP-001 trial enrolled 32 adults who had undergone at least two surgeries in the previous year and had no control group. The efficacy population comprised the 26 who had needed at least three, with a median of 4.5 excisions. The 95% confidence interval around the response rate runs from 12% to 48%, which illustrates how little precision a study of this size offers. Treatment follows standard surgical debulking and consists of four intramuscular doses over nine weeks, delivered with Inovio's CELLECTRA 5PSP electroporation device. Most treatment-related reactions were mild or moderate and transient, and all 32 patients completed the study.

The regulatory route was not assured. The FDA accepted the application in December 2025 with a target date of 30 October, but its acceptance letter carried a preliminary comment questioning whether the application justified the accelerated pathway. Inovio said in August that the agency had not discussed the point at a recent informal meeting, and the approval announcements do not say how the point was resolved. The outcome leaves obligations: Inovio must submit a draft confirmatory protocol by the end of 2026, with the aim of agreeing a final design by mid-2027, and continued approval may depend on verified clinical benefit. As with GSK's Jemperli in rectal cancer and Replimune's Tudriqev in melanoma, the licence is conditional.

That contrasts sharply with the incumbent. Precigen (NASDAQ: PGEN) filed Papzimeos under the accelerated pathway, yet in August 2025 received full approval with no confirmatory trial required. Its open-label, single-arm pivotal study reported that 51% of patients, 18 of 35, needed no surgery in the 12 months after treatment, given as four subcutaneous injections over 12 weeks. Comparing 27% with 51% is tempting but unreliable: these are small, uncontrolled trials in separate patient groups, and neither was designed to test one product against the other. Prescribers will nonetheless notice the gap, and the two labels will invite the comparison.

The market is proving larger than the rarity of the disease suggests. Papzimeos generated net revenue of $53.1 million in the second quarter, more than double the previous quarter, with well over 500 patients registered through Precigen's hub and coverage reaching about 315 million US lives. Inovio estimates that at least 25,000 US patients have the disease. Precigen's shares were reported to have fallen 27% after hours on the news, a reaction that reflects how much of its value rests on being the only option. Inovio has not disclosed a price. It expects product to be available to order in about 60 days, with full field deployment in the first quarter of 2027 through Syneos Health, and scheduled a call for 2 November on the label and launch.

Funding is the immediate constraint. Inovio held $36.7 million at 30 June, before about $18.3 million from a July offering, and in August said its resources would last into late in the first quarter of 2027, excluding further capital raising. That is little margin for a launch. The shares closed down 21.95% at $0.6024 on 30 October, then rose 241.93% to $2.0598 after hours, and a stronger price makes an early equity raise an obvious option, though none has been announced. Precigen, with $38.7 million at the end of June, is also thinly capitalised and targeting cash flow break-even by the end of 2026.

The policy question is how a confirmatory trial can work once a fully approved alternative is on the market. A controlled study of a conditionally approved therapy requires patients willing to accept a comparator when a licensed option with a higher reported response rate exists, in a rare disease. If the FDA's design requirements are demanding, Voceryq's approval may stay conditional for years. If they are lenient, the accelerated pathway will look less like a bridge to evidence than a substitute for it, and rare-disease sponsors will study the final protocol closely.